MedTrace Logo

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

NCT01000740 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2010-05-21

No results posted yet for this study

Summary

The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.

Conditions

Interventions

GENETIC

EGFR Mutation Test

Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.

GENETIC

Ki-67 protein expression

Ki-67 protein expression in tissue will be analysed by IHC method.

Sponsors & Collaborators

Principal Investigators

  • Karen Atkin · AstraZeneca

  • Louis Zhang · AstraZeneca

  • Longyun Li · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01000740 on ClinicalTrials.gov